Current advances and future challenges in adenoviral vector biology and targeting

被引:147
作者
Campos, Samuel K.
Barry, Michael A. [1 ]
机构
[1] Mayo Clin, Dept Internal Med, Dept Immunol, Div Infect Dis,Translat Immunovirol Program,Mol M, Rochester, MN 55902 USA
[2] Univ New Mexico, Sch Med, Dept Mol Genet & Microbiol, Albuquerque, NM 87131 USA
关键词
ad biology; ad trafficking; ad structure;
D O I
10.2174/156652307780859062
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Gene delivery vectors based on Adenoviral (Ad) vectors have enormous potential for the treatment of both hereditary and acquired disease. Detailed structural analysis of the Ad virion, combined with functional studies has broadened our knowledge of the structure/function relationships between Ad vectors and host cells/tissues and substantial achievement has been made towards a thorough understanding of the biology of Ad vectors. The widespread use of Ad vectors for clinical gene therapy is compromised by their inherent immunogenicity. The generation of safer and more effective Ad vectors, targeted to the site of disease, has therefore become a great ambition in the field of Ad vector development. This review provides a synopsis of the structure/function relationships between Ad vectors and host systems and summarizes the many innovative approaches towards achieving Ad vector targeting.
引用
收藏
页码:189 / 204
页数:16
相关论文
共 191 条
  • [1] THE 3-DIMENSIONAL STRUCTURE OF FOOT-AND-MOUTH-DISEASE VIRUS AT 2.9-A RESOLUTION
    ACHARYA, R
    FRY, E
    STUART, D
    FOX, G
    ROWLANDS, D
    BROWN, F
    [J]. NATURE, 1989, 337 (6209) : 709 - 716
  • [2] The subgenus-specific C-terminal region of protein IX is located on the surface of the adenovirus capsid
    Akalu, A
    Liebermann, H
    Bauer, U
    Granzow, H
    Seidel, W
    [J]. JOURNAL OF VIROLOGY, 1999, 73 (07) : 6182 - 6187
  • [3] Blood clearance rates of adenovirus type 5 in mice
    Alemany, R
    Suzuki, K
    Curiel, DT
    [J]. JOURNAL OF GENERAL VIROLOGY, 2000, 81 : 2605 - 2609
  • [4] CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors
    Alemany, R
    Curiel, DT
    [J]. GENE THERAPY, 2001, 8 (17) : 1347 - 1353
  • [5] Next-generation adenoviral vectors: new and improved
    Amalfitano, A
    [J]. GENE THERAPY, 1999, 6 (10) : 1643 - 1645
  • [6] THE PROTEINASE POLYPEPTIDE OF ADENOVIRUS SEROTYPE-2 VIRIONS
    ANDERSON, CW
    [J]. VIROLOGY, 1990, 177 (01) : 259 - 272
  • [7] THE REFINED CRYSTAL-STRUCTURE OF HEXON, THE MAJOR COAT PROTEIN OF ADENOVIRUS TYPE-2, AT 2-CENTER-DOT-9 ANGSTROM RESOLUTION
    ATHAPPILLY, FK
    MURALI, R
    RUX, JJ
    CAI, ZP
    BURNETT, RM
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 1994, 242 (04) : 430 - 455
  • [8] Association of adenovirus with the microtubule organizing center
    Bailey, CJ
    Crystal, RG
    Leopold, PL
    [J]. JOURNAL OF VIROLOGY, 2003, 77 (24) : 13275 - 13287
  • [9] Binding of adenovirus capsid to dipalmitoyl phosphatidylcholine provides a novel pathway for virus entry
    Balakireva, L
    Schoehn, G
    Thouvenin, E
    Chroboczek, J
    [J]. JOURNAL OF VIROLOGY, 2003, 77 (08) : 4858 - 4866
  • [10] Evolution of cell recognition by viruses
    Baranowski, E
    Ruiz-Jarabo, CM
    Domingo, E
    [J]. SCIENCE, 2001, 292 (5519) : 1102 - 1105